News & Events
News & Events
Institut Pasteur Korea Open Call Results: 2 Joint-Research Projects on Cancer Drug Research
2017-07-24
- KAIST and IPK to analyze signaling in cancer cells for enhancing treatments
- Catholic Kwandong Univ. and IPK to identify drug-resistance mechanisms of cancer cells
Pangyo, Gyeonggi, 24 Jul, 2017 | Institut Pasteur Korea (IPK, CEO: Dr. Wang-Shick Ryu) announces the results of the 2017 IPK open call. The aim of the 2017 IPK RNAi Screening open call is to link outstanding research result to industrialization. Two teams were selected, both with a focus on cancer drug: Prof. Yoosik Kim, Dept. of Chemical & Biomolecular Engineering, KAIST and Prof. Hyun Chang, Hematology and Medical Oncology, International ST. Mary’s Hospital, Catholic Kwandong Univ.
Prof. Yoosik Kim, KAIST, and IPK will work to analyze signaling networks for enhancing chemotherapy treatments and Prof. Hyun Chang, Catholic Kwandong Univ., and IPK will focus on identifying drug-resistance mechanisms of cancer cells. David Shum, Team Leader of Assay Development and Screening (ADS), IPK, explains “ADS will set up a collaborative research platform across the institutions and work together to meet the research goals in this complicated disease area. The projects will begin in August.”
Dr. Wang-Shick Ryu, IPK CEO, says “IPK is thrilled the open call has garnered attention from 2 prestigious organizations. We are honored to work with Prof. Yoosik Kim of KAIST and Prof. Hyun Chang of Catholic Kwandong Univ.” He adds, “These projects represent IPK’s commitment to the continued development of Korea’s scientific research field by connecting national research results with drug discovery. It is our hope these two research projects will extend our scope and result in a foundation to address cancer drug research areas.”
IPK’s ‘Phenomic Technologies*’, next-generation drug discovery technology platforms, combine advances from the latest bio-imaging techniques with high throughput screening technologies, to enable the real-time observation and analysis of cellular disease models in a high throughput mode. IPK can also identify previously unknown target genes associated with diseases and find new compounds that can serve as leads for innovative drug discovery. Prof. Yoosik Kim and Prof. Hyun Chang’s research teams will be provided with assay development support and a pilot RNAi screen at no cost to discover and identify novel drug targets for developing first-in-class drugs.
.jpg)
*Phenomic Technologies: next-generation drug discovery technology platforms
# # # # # #
About Institut Pasteur Korea
Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and an economic growth engine that contributes to Korea's scientific intellectual and technical resources. IPK has four core missions of public interest; 1) Research, combining front line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases, 2) Education, offering a wide range of programming to nurture the development of the next generation of scientists and health professionals, 3) Public Health, working in collaboration with national and international health authorities, and 4) Translation of biomedical discoveries to improve health via technology transfer and industrial partnerships.
IPK is a member of the Institut Pasteur International Network (Network). As a hub institution, IPK plays a key role in the Network, serving as a bridge between Korea and global bio-pharma science, expanding Korea's R&D base collaborative research projects with global alliances
The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science, ICT and Future Planning (MSIP). IPK also has a great supporter in the Gyeonggi Provincial government (2005 – 2015 : Block funding | 2016 – Present : drug discovery co-resarch fund for pharm industries).
- Catholic Kwandong Univ. and IPK to identify drug-resistance mechanisms of cancer cells
Pangyo, Gyeonggi, 24 Jul, 2017 | Institut Pasteur Korea (IPK, CEO: Dr. Wang-Shick Ryu) announces the results of the 2017 IPK open call. The aim of the 2017 IPK RNAi Screening open call is to link outstanding research result to industrialization. Two teams were selected, both with a focus on cancer drug: Prof. Yoosik Kim, Dept. of Chemical & Biomolecular Engineering, KAIST and Prof. Hyun Chang, Hematology and Medical Oncology, International ST. Mary’s Hospital, Catholic Kwandong Univ.
Prof. Yoosik Kim, KAIST, and IPK will work to analyze signaling networks for enhancing chemotherapy treatments and Prof. Hyun Chang, Catholic Kwandong Univ., and IPK will focus on identifying drug-resistance mechanisms of cancer cells. David Shum, Team Leader of Assay Development and Screening (ADS), IPK, explains “ADS will set up a collaborative research platform across the institutions and work together to meet the research goals in this complicated disease area. The projects will begin in August.”
Dr. Wang-Shick Ryu, IPK CEO, says “IPK is thrilled the open call has garnered attention from 2 prestigious organizations. We are honored to work with Prof. Yoosik Kim of KAIST and Prof. Hyun Chang of Catholic Kwandong Univ.” He adds, “These projects represent IPK’s commitment to the continued development of Korea’s scientific research field by connecting national research results with drug discovery. It is our hope these two research projects will extend our scope and result in a foundation to address cancer drug research areas.”
IPK’s ‘Phenomic Technologies*’, next-generation drug discovery technology platforms, combine advances from the latest bio-imaging techniques with high throughput screening technologies, to enable the real-time observation and analysis of cellular disease models in a high throughput mode. IPK can also identify previously unknown target genes associated with diseases and find new compounds that can serve as leads for innovative drug discovery. Prof. Yoosik Kim and Prof. Hyun Chang’s research teams will be provided with assay development support and a pilot RNAi screen at no cost to discover and identify novel drug targets for developing first-in-class drugs.
*Phenomic Technologies: next-generation drug discovery technology platforms
Ø PhenomicScreen™ - a visual– and cell-based high throughput/ high content target-free screening platform. It quantifies biological events in living cells and allows the cells themselves to identify the most effective drug targets from millions of complex molecular interactions.
Ø PhenomicID™ - assesses the impact of genes in the cell by turning off each gene, one by one. The entire human genome and focused gene sets are available for screening using cell imaging technology to identify physiologically-relevant molecular pathways and targets involved in the development of the phenotype of the diseases under study.
Ø PhenomicID™ - assesses the impact of genes in the cell by turning off each gene, one by one. The entire human genome and focused gene sets are available for screening using cell imaging technology to identify physiologically-relevant molecular pathways and targets involved in the development of the phenotype of the diseases under study.
# # # # # #
About Institut Pasteur Korea
Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and an economic growth engine that contributes to Korea's scientific intellectual and technical resources. IPK has four core missions of public interest; 1) Research, combining front line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases, 2) Education, offering a wide range of programming to nurture the development of the next generation of scientists and health professionals, 3) Public Health, working in collaboration with national and international health authorities, and 4) Translation of biomedical discoveries to improve health via technology transfer and industrial partnerships.
IPK is a member of the Institut Pasteur International Network (Network). As a hub institution, IPK plays a key role in the Network, serving as a bridge between Korea and global bio-pharma science, expanding Korea's R&D base collaborative research projects with global alliances
The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science, ICT and Future Planning (MSIP). IPK also has a great supporter in the Gyeonggi Provincial government (2005 – 2015 : Block funding | 2016 – Present : drug discovery co-resarch fund for pharm industries).